Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of Dupixent in the European Union to treat adults and adolescents with eosinophilic esophagitis. This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not candidates for conventional medicinal therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In May 2022, Dupixent 300 mg weekly was approved by the U.S. FDA for the treatment of patients aged 12 years and older, weighing at least 40 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron, Sanofi announce EC expansion for Dupixent marketing authorization
- Regeneron announces data on trial of odronextamab to treat R/R FL
- Regeneron announces data from Phase 2 trial of linvoseltamab
- Regeneron announces data from trials evaluating investigational odronextamab
- Regeneron’s fianlimab and Libtayo featured in solid tumor presentations